Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
RESEARCH TOOLSreports
Karyopharm Therapeutics (KPTI) Stock Price & Analysis
921 Followers
KPTI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.11 - $6.01
Previous Close$1.25
Volume862.41K
Average Volume (3M)2.36M
Market Cap
$142.94M
Enterprise ValueN/A
Total Cash (Recent Filing)$237.33M
Total Debt (Recent Filing)$178.08M
Price to Earnings (P/E)-0.9
Beta1.55
Next Earnings
Nov 06, 2023EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.47
Shares Outstanding114,354,540
10 Day Avg. Volume1,063,111
30 Day Avg. Volume2,356,258
Standard Deviation0.21
R-Squared0.00001
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-1.83
Price to Sales (P/S)3.62
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$6.71Price Target Upside436.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Karyopharm Therapeutics News
Pre-EarningsKPTI Upcoming Earnings Report: What to Expect?
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $1.11 and its highest was $6.01 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Currently, no data Available
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Nov 06, 2023 which is in 45 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on Aug 02, 2023. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.342 by $0.052.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -$0.28.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 114,354,540 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.342. Following the earnings report the stock price went down -0.556%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Among the largest hedge funds holding Karyopharm Therapeutics’s share is Platinum Investment Management. It holds Karyopharm Therapeutics’s shares valued at 895K.
---
Karyopharm Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.71 (436.80% Upside)
$6.71 (436.80% Upside)
Blogger Sentiment
Bullish
KPTI Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 326.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $49.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.12%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
---
Top 5 ETFs holding KPTI
Vanguard Total Stock Market ETF
$4.36M
iShares Russell 3000 ETF
$27.84K
Vanguard Russell 3000 ETF
$7.96K
Up to five ETFs with an Outperform Smart Score that hold KPTI. The ETFs are listed according to market value of KPTI within the ETF
---